Phase 1 N=25 A Phase 1 Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of MEDI0639 in Advanced Solid Tumors
Solid Tumors
Primary: Maximum Tolerated Dose (MTD) of MEDI0639 — NA milligram (mg)
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=20 Hepatitis B Vaccine in Chronic Hepatitis B Patients With Low Serum HBsAg
Chronic Hepatitis B
Primary: Change in HBsAg Levels From Baseline to 2 Years — -0.27 log IU/ml — p=<0.05
Phase 1 N=82 Study in Healthy Subjects to Compare the Concentrations of the Omega-3 Fatty Acids EPA and DHA in Blood When Delivered as Three New Capsules in Relation to the Epanova® Capsule Under Fasting and Fed Conditions
Relative Bioavailability · AUC · Cmax
Primary: Area Under the Plasma Concentration-time Curve From Zero to Infinity (AUC) Assessed for Eicosapentaenoic Acid (EPA) After Administration of Test Formulation 1, 2 and 3…
Phase 1 N=31 Yervoy With Sylatron Unresectable Stage 3 or 4 Melanoma
Melanoma
Primary: Maximum Tolerated Dose (MTD) of Sylatron — 2 μg/kg s
Phase 1 N=26 Drug Interaction Study With Ribavirin and Abacavir in Male Subjects With Hepatitis C Who Have Failed Ribavirin Treatment
Hepatitis C · HIV
Primary: Ribavirin Triphosphate (RBV-TP) Intracellular Concentrations — 15.87; 15.93 picomoles per 10^6 cells
Phase 1 N=16 Study to Evaluate Single Inhaled Doses of PT001, PT003, PT005 and PT001 Plus PT005 in Healthy Subjects
Healthy Volunteers
Primary: Symptoms of Dry Mouth — 3; 1; 3; 1 Participants
Phase 1 N=49 Evaluate PF-00547659 On Cerebrospinal Fluid Lymphocytes In Volunteers With Crohn's Disease Or Ulcerative Colitis Who Failed Or Did Not Tolerate Anti-TNFs
Crohn's Disease · Ileitis · Ileo-colonic and Colonic Crohn's Disease
Primary: Cohort 2: Baseline Absolute Lymphocyte Count in Cerebrospinal Fluid (CSF) — 338.5 cells per milliliter (cells/mL)
Phase 1 N=95 PK Study of PT003 and PT001 in Japanese Healthy Subjects
COPD
Primary: Cmax — 15.23; 9.09; 16.85; 7.26 pg/mL
Phase 1 N=30 Bioavailability of Different Applications of Dabigatran in Healthy Volunteers
Healthy
Primary: AUC0-inf for Total Dabigatran — 599; 1050; 928 ng(nanogram)*h(hour)/mL(milliliter)
Phase 1 N=31 Mild, Moderate and Severe Renal Impairment Study
Gout
Primary: Maximum Observed Plasma Concentration (Cmax) — 25.6; 29.0; 38.2; 16.7 ng/mL
Phase 1 N=35 Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative Diseases
Primary Myelofibrosis (PMF) · Post-Polycythaemia Vera · Essential Thrombocythaemia Myelofibrosis
Primary: Pharmacokinetic Parameters Following Single Dosing: AUC0-12 — 69.2; 295; 278; 1860 ug*h/L
Phase 1 N=60 Safety of Lactobacillus Reuteri in Healthy Children Ages 2 to 5 Years in Peru
Healthy
Primary: Number of Participants With Positive Blood Culture for L Reuteri — 0; 0 Participants
Phase 1 N=30 A Study of Baricitinib and Omeprazole in Healthy Participants
Healthy Volunteers
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib — 99.2; 76.8 nanograms/milliliter (ng/mL)
Phase 1 N=16 A Study of Baricitinib in Healthy Japanese Participants
Healthy Participants
Primary: Pharmacokinetics (PK): Area Under the Concentration Versus Time Curve From Zero to Infinity (AUC[0-∞]) of Baricitinib — 626; 584; 297; 301 nanogram*hour/milliliter…
Phase 1 N=16 A Pharmacokinetic Study of Baricitinib in Participants With Liver Disease
Liver Diseases · Hepatic Insufficiency
Primary: Pharmacokinetics (PK): Maximum Concentration (Cmax) of Baricitinib (LY3009104) — 35.3; 38.2 nanograms per milliliter (ng/mL)